CO5640152A2 - Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c - Google Patents
Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis cInfo
- Publication number
- CO5640152A2 CO5640152A2 CO05110321A CO05110321A CO5640152A2 CO 5640152 A2 CO5640152 A2 CO 5640152A2 CO 05110321 A CO05110321 A CO 05110321A CO 05110321 A CO05110321 A CO 05110321A CO 5640152 A2 CO5640152 A2 CO 5640152A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cycloalkyl
- halogen
- alkoxy
- cycloalkoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Abstract
1.- Una composición farmacéutica que comprende:(a) un compuesto de fórmula (I): en la que:------ indica un enlace opcional que forma un doble enlace entre las posiciones 13 y 14;R1 es H, halógeno, alquilo C1-6, cicloalquilo C3-6, halógenoalquilo C1-6, alcoxi C1-6, cicloalcoxi C3-6, hidroxi, o N(R5)2, en el que cada R5 es independientemente H, alquilo C1-6 o cicloalquilo C3-6;R2 es H, halógeno, alquilo C1-6, cicloalquilo C3-6, halógenoalquilo C1-6, tioalquilo C1-6, alcoxi C1-6, cicloalcoxi C3-6, alcoxialquilo C2-7, arilo o Het C6 ó 10, en el que Het es un heterociclo saturado o insaturado, de cinco, seis o siete miembros que contiene de uno a cuatro heteroátomos en el anillo seleccionados de nitrógeno, oxigeno y azufre;estando dicho cicloalquilo, arilo o Het opcionalmente sustituido con R6, en el que R6 es H, halógeno, alquilo C1-6, cicloalquilo C3-6, alcoxi C1-6, cicloalcoxi C3-6, NO2, N(R7)2, NH-C(O)-R7; o NH-C(O)-NH-R7, en los que cada R7 es independientemente:H, alquilo C1-6 o cicloalquilo C3-6;o R6 es NH-C(O)-OR8, en el que R8 es alquilo C1-6 o cicloalquilo C3-6;R3 es R9O- o R9NH-, en los que R9 es alquilo C1-6 o cicloalquilo C3-6;R4 es H o de uno a tres sustituyentes en cualquier átomo de carbono disponible en las posiciones 8, 9, 10, 11, 12, 13 ó 14, seleccionado dicho sustituyente independientemente del grupo que consta de: alquilo C1-6, halógenoalquilo C1-6, alcoxi C1-6, hidroxi, halógeno, amino, oxo, tio o tioalquilo C1-6.o uno de sus tautómeros;(b) aproximadamente 0,1 a 10% en peso de una amina farmacéuticamente aceptable o una mezcla de aminas farmacéuticamente aceptables; ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45976503P | 2003-04-02 | 2003-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5640152A2 true CO5640152A2 (es) | 2006-05-31 |
Family
ID=33310709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05110321A CO5640152A2 (es) | 2003-04-02 | 2005-10-28 | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c |
Country Status (24)
Country | Link |
---|---|
US (1) | US7157424B2 (es) |
EP (1) | EP1613353A1 (es) |
JP (1) | JP2006522017A (es) |
KR (1) | KR20050108420A (es) |
CN (1) | CN100363055C (es) |
AR (1) | AR043795A1 (es) |
AU (1) | AU2004231538A1 (es) |
BR (1) | BRPI0409068A (es) |
CA (1) | CA2520886A1 (es) |
CO (1) | CO5640152A2 (es) |
EA (1) | EA010013B1 (es) |
EC (1) | ECSP056065A (es) |
HK (1) | HK1091130A1 (es) |
HR (1) | HRP20050871A2 (es) |
MX (1) | MXPA05010338A (es) |
NO (1) | NO20055057L (es) |
NZ (1) | NZ543250A (es) |
PE (1) | PE20050013A1 (es) |
RS (1) | RS20050741A (es) |
TW (1) | TW200505484A (es) |
UA (1) | UA81028C2 (es) |
UY (1) | UY28250A1 (es) |
WO (1) | WO2004093915A1 (es) |
ZA (1) | ZA200506019B (es) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
KR20060094083A (ko) * | 2003-09-22 | 2006-08-28 | 베링거 인겔하임 인터내셔날 게엠베하 | C형 간염 바이러스에 대해 활성인 마크로사이클릭펩타이드 |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
DE602005025855D1 (de) * | 2004-01-21 | 2011-02-24 | Boehringer Ingelheim Pharma | Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus |
RS51243B (sr) | 2004-01-30 | 2010-12-31 | Medivir Ab. | Inhibitori ns-3 serina hcv proteaze |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7879797B2 (en) | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7470664B2 (en) * | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
EP1924594A2 (en) * | 2005-07-25 | 2008-05-28 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
JP4705984B2 (ja) | 2005-08-01 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Hcvns3プロテアーゼ阻害剤としての大環状ペプチド |
WO2007044893A2 (en) | 2005-10-11 | 2007-04-19 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis c viral replication |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US8268776B2 (en) | 2006-06-06 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US20070281884A1 (en) * | 2006-06-06 | 2007-12-06 | Ying Sun | Macrocyclic oximyl hepatitis C protease inhibitors |
US9526769B2 (en) | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
AU2007309546A1 (en) * | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
EP2079479B1 (en) | 2006-10-24 | 2014-11-26 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
CA2667266C (en) | 2006-10-24 | 2015-11-24 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US8377874B2 (en) * | 2006-10-27 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US20100099695A1 (en) * | 2006-10-27 | 2010-04-22 | Liverton Nigel J | HCV NS3 Protease Inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2121707B1 (en) * | 2006-12-20 | 2012-12-05 | Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. | Antiviral indoles |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0625345D0 (en) * | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EA200971026A1 (ru) * | 2007-05-03 | 2011-02-28 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликации вируса гепатита с |
MX2009012093A (es) * | 2007-05-10 | 2010-01-25 | Intermune Inc | Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c. |
CA2693537C (en) | 2007-07-17 | 2013-06-25 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
US8927569B2 (en) * | 2007-07-19 | 2015-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as antiviral agents |
GB2451811A (en) * | 2007-08-09 | 2009-02-18 | Ems Sa | Delivery composition for solubilising water-insoluble pharmaceutical active ingredients |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
WO2009070692A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
WO2009070689A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
WO2009073780A1 (en) | 2007-12-06 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Process for making macrocyclic oximyl hepatitis c protease inhibitors |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
JP5608563B2 (ja) | 2008-02-25 | 2014-10-15 | メルク・シャープ・アンド・ドーム・コーポレーション | 治療用化合物 |
CA2720729A1 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009134624A1 (en) | 2008-04-28 | 2009-11-05 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
DE102008022520A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009148923A1 (en) | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
DK2310095T3 (da) | 2008-07-22 | 2012-12-10 | Merck Sharp & Dohme | Makrocykliske quinoxalinforbindelser som hcv-ns3-protease-inhibitorer |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2009335904A1 (en) | 2008-12-19 | 2011-08-04 | Gilead Sciences, Inc. | HCV NS3 protease inhibitors |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
MX2011013824A (es) | 2009-07-07 | 2012-01-30 | Boehringer Ingelheim Int | Composicion farmaceutica para un inhibidor de proteasa del virus de la hepatitis c. |
US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
NZ602288A (en) * | 2010-03-10 | 2014-02-28 | Abbvie Bahamas Ltd | Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide |
EP2651885A1 (en) * | 2010-12-16 | 2013-10-23 | Abbvie Inc. | Anti-viral compounds |
SG191759A1 (en) | 2010-12-30 | 2013-08-30 | Enanta Pharm Inc | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
CA2822556A1 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
US20120213855A1 (en) * | 2011-02-17 | 2012-08-23 | Cima Labs Inc. | Dosage forms for weakly ionizable compounds |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8912141B2 (en) | 2011-06-23 | 2014-12-16 | Panmed Ltd. | Treatment of hepatitis C virus |
US9328138B2 (en) | 2011-11-15 | 2016-05-03 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
BR112015007887A2 (pt) | 2012-10-08 | 2017-07-04 | Abbvie Inc | compostos úteis para produzir inibidores hcv protease |
BR112015007879A2 (pt) | 2012-10-19 | 2017-07-04 | Bristol Myers Squibb Co | inibidores do vírus da hepatite c |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914614B1 (en) * | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
CN103965286B (zh) * | 2014-04-22 | 2017-11-03 | 南京安赛莱医药科技有限公司 | 丙型肝炎病毒(hcv)ns3蛋白酶抑制剂 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2184310T3 (es) * | 1997-07-29 | 2003-04-01 | Upjohn Co | Formulacion autoemulsionante para compuestos lipofilos acidos. |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
KR20060094083A (ko) | 2003-09-22 | 2006-08-28 | 베링거 인겔하임 인터내셔날 게엠베하 | C형 간염 바이러스에 대해 활성인 마크로사이클릭펩타이드 |
-
2004
- 2004-03-23 UA UAA200510334A patent/UA81028C2/uk unknown
- 2004-03-23 KR KR1020057018703A patent/KR20050108420A/ko not_active Application Discontinuation
- 2004-03-23 MX MXPA05010338A patent/MXPA05010338A/es active IP Right Grant
- 2004-03-23 BR BRPI0409068-3A patent/BRPI0409068A/pt not_active IP Right Cessation
- 2004-03-23 JP JP2006501244A patent/JP2006522017A/ja active Pending
- 2004-03-23 AU AU2004231538A patent/AU2004231538A1/en not_active Abandoned
- 2004-03-23 CA CA002520886A patent/CA2520886A1/en not_active Abandoned
- 2004-03-23 EP EP04759731A patent/EP1613353A1/en not_active Withdrawn
- 2004-03-23 US US10/807,023 patent/US7157424B2/en active Active
- 2004-03-23 RS YUP-2005/0741A patent/RS20050741A/sr unknown
- 2004-03-23 CN CNB2004800087739A patent/CN100363055C/zh not_active Expired - Fee Related
- 2004-03-23 WO PCT/US2004/008837 patent/WO2004093915A1/en active Application Filing
- 2004-03-23 EA EA200501532A patent/EA010013B1/ru not_active IP Right Cessation
- 2004-03-23 NZ NZ543250A patent/NZ543250A/en unknown
- 2004-03-31 AR ARP040101067A patent/AR043795A1/es active Pending
- 2004-03-31 TW TW093108968A patent/TW200505484A/zh unknown
- 2004-03-31 UY UY28250A patent/UY28250A1/es not_active Application Discontinuation
- 2004-03-31 PE PE2004000340A patent/PE20050013A1/es not_active Application Discontinuation
-
2005
- 2005-07-27 ZA ZA200506019A patent/ZA200506019B/en unknown
- 2005-09-30 EC EC2005006065A patent/ECSP056065A/es unknown
- 2005-09-30 HR HR20050871A patent/HRP20050871A2/xx not_active Application Discontinuation
- 2005-10-28 CO CO05110321A patent/CO5640152A2/es not_active Application Discontinuation
- 2005-10-31 NO NO20055057A patent/NO20055057L/no not_active Application Discontinuation
-
2006
- 2006-10-26 HK HK06111837A patent/HK1091130A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ECSP056065A (es) | 2006-01-27 |
TW200505484A (en) | 2005-02-16 |
EA010013B1 (ru) | 2008-06-30 |
HK1091130A1 (en) | 2007-01-12 |
EA200501532A1 (ru) | 2006-06-30 |
AR043795A1 (es) | 2005-08-10 |
US7157424B2 (en) | 2007-01-02 |
NO20055057L (no) | 2005-10-31 |
PE20050013A1 (es) | 2005-03-01 |
CN100363055C (zh) | 2008-01-23 |
KR20050108420A (ko) | 2005-11-16 |
ZA200506019B (en) | 2006-07-26 |
NZ543250A (en) | 2008-12-24 |
UA81028C2 (en) | 2007-11-26 |
UY28250A1 (es) | 2004-11-30 |
BRPI0409068A (pt) | 2006-03-28 |
CN1767856A (zh) | 2006-05-03 |
RS20050741A (en) | 2007-06-04 |
EP1613353A1 (en) | 2006-01-11 |
WO2004093915A1 (en) | 2004-11-04 |
JP2006522017A (ja) | 2006-09-28 |
MXPA05010338A (es) | 2005-11-17 |
US20040229776A1 (en) | 2004-11-18 |
CA2520886A1 (en) | 2004-11-04 |
HRP20050871A2 (en) | 2006-10-31 |
AU2004231538A1 (en) | 2004-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5640152A2 (es) | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
CO5611167A2 (es) | Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c | |
ECSP088150A (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
AR054882A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
AR044909A1 (es) | Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia | |
AR045761A1 (es) | Derivados de 2-piridona como inhibidores de elastasa de neutrofilos | |
AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
AR063101A1 (es) | Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2. | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
CL2004000076A1 (es) | Compuestos derivados de indol, inhibidores de polimerasa, sales; composicion farmaceutica que los comprende; procedimiento de preparacion de dichos compuestos; compuestos intermediarios; y uso del compuesto para tratar una infeccion causada por el vi | |
AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
AR048974A1 (es) | Derivados sustituidos del dioxido de oxazol-benzoisotiazol y composiciones farmaceuticas. | |
AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
AR015512A1 (es) | Derivados ciclicos n-acilo amina, un procedimiento para su preparacion, un intermediario y una composicion farmaceutica | |
ECSP11010946A (es) | Nuevos compuestos heterocíclicos nitrogenados, preparación de los mismos y utilización de los mismos como medicamentos antibacterianos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |